|
|
 |
|
Viewing report
|
|
|
|
Antihypertensives - Weak Pipeline Leaves Innovation to Novartis
Datamonitor, March 2006, Pages: 185
Despite modest improvements in blood pressure control, effective blood pressure control for all still seems to be an elusive goal. As such, the promotion and use of combination therapies has increased, explaining much of the current R&D activity in this area where many developers are studying novel combinations of currently marketed drugs rather than discovering innovative treatments
Scope of this title:
- Evaluation of patient potential for developmental antihypertensives over the period 2006-2015
- Scrutiny of key impacts on the R&D approach and cost, evaluation of optimal clinical trial end points and identification of suitable comparators
- Evaluation of key players in the hypertensive market and opposing company approaches to development and commercialization
- Analysis of key antihypertensive drugs in development and their ability to satisfy major unmet needs and compete with existing agents
Highlights of this title:
The use of fixed dose combination (FDC) therapy will continue to grow substantially over the forecast period, exceeding the growth of single pill alternatives. Despite FDCs forming an essential part of a strategy for controlling hypertension, their development is starving innovation within antihypertensive R&D
Rasilez, the only real innovation in the current pipeline, will be the first oral renin inhibitor to be launched. Its ability to proximally block the renin angiotensin system (RAS), combined with its true 24-hour activity, means it may offer specific advantages over other drug classes, and is likely to become a blockbuster by 2010
Despite continued research into other hypertension targets such as endothelin and vasopeptidase poor safety records, lack of efficacy compared to other classes and a low patient potential, these agents promise to be no more than an academic interest rather than providing physicians with a real alternative in treating hypertension
Reasons to order your copy:
- Understand physician sentiment on renin inhibitors as the next innovative drug class, and the threats faced by existing and developmental products
- View independent sales forecasts for products in late stage development for treatment of hypertension in both existing and novel classes
- Identify early stage antihypertensive compounds with high potential being developed by companies seeking a marketing partner
Customers who bought this item also bought
Renin Inhibitors: A Novel Approach to Hypertension
Pipeline Insight: Antihypertensives - Together We Stand, Divided We Fail
Anti-Hypertensive Drugs - Global Strategic Business Report
Hypertension And Diabetic Kidney Disease - Prevalence, Current Treatment And Future Options
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Competitor Analysis: Antihypertensives
Hypertension: Competing Treatments and Market Entry Considerations
Hypertension: Treatments and Prescribing Practices - A Global Survey
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Hypertension - Multiple Layers of Therapy Cover all Eventualities
Target Product Profiles 2010: Physician Insights on Key Attributes: Hypertension
|
|
|
|
